Description: MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.
Home Page: www.meiragtx.com
MGTX Technical Analysis
430 East 29th Street
New York,
NY
10016
United States
Phone:
646 860 7985
Officers
| Name | Title |
|---|---|
| Dr. Alexandria Forbes | CEO, Pres & Director |
| Mr. Richard Brian Giroux B.A. | COO & CFO |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer |
| Mr. Robert J. Wollin J.D. | Gen. Counsel & Sec. |
| Dr. Stuart Naylor Ph.D. | Chief Devel. Officer |
| Dr. Michel Michaelides M.D. | Head of Clinical Ophthalmology |
| Ms. Christine Elise Sheehy | Sr. VP of Global Integration |
| Mr. Joel P. Brooks | Sr. VP of Fin. |
| Mr. Tim Randall | Sr. VP of Risk & Internal Controls |
| Dr. Alastair Leighton Ph.D. | Sr. VP of Manufacturing & Supply Chain |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2204 |
| Price-to-Sales TTM: | 6.4573 |
| IPO Date: | 2018-06-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 361 |